Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits.
Leopoldo Baiza-DuránAlejandra Sánchez-RíosJoel González-BarónOscar Olvera-MontañoElba Correa-GallegosAndrea Navarro-SánchezPatricia Del Carmen Muñoz-VillegasPublished in: International journal of retina and vitreous (2020)
Our study did not find evidence of retinal toxicity from a repeated intravitreal injection of PRO-169 or ranibizumab (Lucentis®) in NZW rabbits. These findings support intravitreal PRO-169 as a safe candidate to develop as a future alternative for the treatment of retinal neovascularization diseases.